SMY Pharma, the flagship enterprise of the Shwe Mya Yar Group of Companies, was established on January 26, 2022, with a vision to enhance public health in Myanmar through the research, development, and manufacturing of high-quality pharmaceutical products.

Driven by scientific excellence and innovation, SMY Pharma places strong emphasis on research-based formulation development for generic molecules to create medicines that are safe, effective, and reliable.

Committed to maintaining the highest standards, SMY Pharma operates under stringent quality management systems aligned with internationally recognized regulatory requirements. Guided by its “Quality First” philosophy, the company adopts disciplined and streamlined manufacturing practices together with continuous improvement initiatives to ensure consistent product quality, safety, and efficacy across its portfolio.With a robust portfolio of products ranging from essential medicines to advanced therapeutic solutions, SMY Pharma strives to enhance the quality of life for millions. We prioritize stringent quality standards, invest in cutting-edge technology, and adhere to international best practices in all aspects of our operations.

Guided by a vision to create a healthier Myanmar, SMY Pharma collaborates with healthcare professionals, policymakers, and communities to drive positive change in the pharmaceutical landscape. Our focus remains on innovation, sustainability, and the well-being of the people we serve.

At SMY Pharma, we don’t just provide medicine; we foster trust, care, and a commitment to a healthier tomorrow.